Introduction
Lung cancer is predominantly a disease of the elderly. More than two-thirds of lung cancer cases occur in persons aged ≥65 years, and the median age at diagnosis is 70 years 1 . Therefore, establishing an effective treatment for elderly patients with lung cancer has become increasingly important. Older adults continue to be underrepresented in clinical trials, and studies designed specifically for this age group are rare 2, 3 . Prospective elderly-specific trials for locally advanced stage III non-small cell lung cancer (NSCLC) provide little evidence. As of now, concurrent chemotherapy with radiotherapy (RT) is the proven standard of care for stage III NSCLC 4, 5 . Compared with sequential chemoradiotherapy, concurrent chemoradiotherapy showed an absolute benefit of 4.5% at 5 years in a meta-analysis 6 . As for the toxicity, the incidence of esophagitis increased. No increase in the risk of pulmonary toxicity was found. Older patients are more susceptible to adverse events. A key question is whether elderly patients can receive the same treatments and derive the same benefit as their younger counterparts.
Pattern of Treatment in the Elderly with Lung Cancer
The pattern of treatment and survival are largely unknown for older patients with stage III NSCLC. Driessen . Among the patients with stage III NSCLC, a substantial proportion of patients aged 40-64 years received combination therapy comprising of RT and pharmacotherapy (34.6%); <10% of the patients in the ≥85-year age group received such therapy (2.3%). On the other hand, 3.1% of the patients in the 40-to 64-year age group and 51.0% of those in the ≥85-year age group received no treatment. Consequently, the treatment choices for stage III NSCLC differ according to age. The reason for that is not mentioned in these studies. However, we can infer that the reasons could be physician decision, patient refusal, concomitant medical problems, and caregiver decision (due to cognitive impairment, etc.).
RT Alone for the Elderly
Thoracic RT alone was the standard treatment for stage III NSCLC. A retrospective examination revealed that a definitive RT of ≥60 Gy was tolerable and feasible in elderly people aged ≥75 years . Forty patients aged ≥75 years with a Karnofsky performance status (PS) score of ≥60 who were unfit to receive an aggressive combined treatment were included in the study. Their median survival time (MST) was 19 months. Their 3-and 5-year survival rates were 18% and 12%, respectively. Joo et al. reported a retrospective analysis of the effectiveness of RT of >60 Gy administered alone in patients with NSCLC who were unfit or rejected for combination treatment
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. Of the patients, 48% had an ECOG PS score of 2 or 3. The MST was 18.6 months for all the patients. For the patients with stage II and III NSCLC, the MST was 24.0 and 18.3 months, respectively. RT alone showed promising results. In this study, the patients were treated using modern techniques such as three-dimensional conformal RT (3-D CRT) or intensity-modulated RT (IMRT), involved-field RT, and a dose of >60 Gy.
A highly accurate RT by innovators in RT and the imaging technique is expected to improve the effect and safety profiles.
Comparison between RT Alone and Combination Therapy in the Elderly
The Japan Clinical Oncology Group (JCOG) trial (JCOG0301) was conducted to determine whether daily lowdose carboplatin plus RT has a greater impact than RT alone on the survival of elderly patients with unresectable locally advanced NSCLC In the patients in the CRT arm, leukocytopenia, neutropenia, and thrombocytopenia were more prevalent than in the patients in the RT arm. A higher incidence of infection was observed in the CRT arm, which reflected a higher incidence of neutropenia. However, the infections were manageable with the appropriate treatments. This trial demonstrated the clinically significant benefits of concurrent daily low-dose carboplatin therapy and thoracic RT in elderly patients.
Subgroup Analysis by Age in the Concurrent Chemoradiotherapy Group
Age-specific subgroup analyses of randomized trials to compare the impact of concurrent chemoradiotherapy have been reported (Table 1 ). The survival data of these studies showed similarities between the <70-and ≥70-year age groups [13] [14] [15] [16] . With regard to toxicities, elderly patients showed higher incidence rates of hematotoxicity and renal failure 13 . Pneumonitis was more frequent in the elderly patients, but grade ≥3 hematotoxicity, esophagitis, and pneumonitis showed no significant differences 16 . The current standard of care for locally advanced NSCLC is combined concurrent therapy with a platinumbased regimen. A pooled analysis reported that elderly patients had higher toxicity and poorer survival after concurrent chemoradiotherapy 17 . Grade 5 adverse events occurred in 9.0% of the elderly patients and in 4.4% of the younger patients. Therefore, whether platinum-doublet chemotherapy is effective and tolerable for a wide range of age groups remains unclear.
Single Agent Chemotherapy with RT in Elderly

S-1
S-1 is an oral anticancer agent comprising of tegafur, gimeracil, and oteracil at a molar ratio of 1:0.4:1 18 . A phase II study of oral S-1 as a single agent for the treatment of advanced NSCLC yielded a response rate of 22% and a MST of 10.2 months 19 . Recently, S-1 is equally as efficacious as docetaxel therapy for patients with previously treated advanced NSCLC 20 . The preclinical synergistic activity of S-1 with RT and its favorable toxicity profile have led to clinical trials that evaluated S-1 in chemoradiotherapy regimens in elderly patients mainly in Japan ( Table 2 ). The Okayama lung cancer study group conducted phase I and II studies of S-1 with thoracic RT in elderly patients aged ≥76 years 21, 22 . In the phase II study, 30 patients were enrolled, the response rate was 63% and the MST was 27.9 months.
Hasegawa et al. reported a phase I study of S-1 with concurrent RT in elderly patients aged ≥70 years 23 . The overall response rate was 83.3%, and the MST was 34.0 months.
Vinorelbine, pemetrexed
Single-agent of pemetrexed or vinorelbine for use in concurrent RT have been investigated in elderly patients with stage III NSCLC 24, 25 . These combinations seem not feasible for elderly patients because of a high incidence of sever pneumonitis.
Carboplatin doublet combination
The efficacy of doublet drug in combination with RT in elderly patients was investigated. A retrospective analysis of weekly administration of paclitaxel and carboplatin with . Twenty-eight patients were enrolled in this study. The median age was 77 years (range, 71-83 years). The response rate was 71.4%. The median OS was 25.0 months. Grade ≥3 pneumonitis was 18%. Although carboplatin plus S-1 and concurrent thoracic RT had promising efficacy in elderly patients with locally advanced NSCLC, radiation pneumonitis was frequently observed with the therapy as compared with single-agent chemotherapy carboplatin or S-1.
Cetuximab
A phase II study of cetuximab and RT in the elderly and/or patients with poor performance status was reported. In this study, patients aged ≥65 years with an ECOG PS score of 0-2 and patients aged <65 and ≥18 years with a PS score of 2 were evaluated
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. The response rate was 26%. The median survival was 15.1 months (95% CI, 5.8-8.6). No treatment-related deaths occurred, but 31 (53.4%) of 58 patients experienced grade ≥3 adverse events. The RTOG 0617 phase III trial investigated the use of cetuximub with standard and highdose chemoradiotherapy 29 . This trial recruited patients aged ≥18 years. It was not an elderly-specific trial. The addition of cetuxumab to chemoradiotherapy did not provide any survival benefit while increasing toxicities.
Emerging Immunotherapy in Stage III NSCLC
Durvalumab is a fully human IgG1 monoclonal antibody that blocks PD-L1 30 . The PACIFIC study assessed the efficacy of durvalumab as a consolidation therapy in comparison with a placebo in patients with stage III, locally advanced, unresectable NSCLCs after platinum-based chemoradiotherapy 31 . The median PFS was 16.8 months with durvalumab and 5.6 months with placebo (HR, 0.52; P<0.001). The safety profile was similar between the arms. The most common grade 3 or 4 adverse event was pneumonia (4.4% in the durvalumab arm vs 3.8% in the placebo arm). A subgroup analysis revealed a PFS benefit with durvalumab across all prespecified prognostic factors. The HR by age was 0.43 (95% CI, 0.32-0.57) in the <65-year age group and 0.74 (95% CI, 0.54-1.01) in the ≥65-year age group. Therefore, immune checkpoint inhibitors will also play an increasing role in the treatment for elderly patients with stage III NSCLC. Attention must be paid to immune-mediated adverse events.
Integration of Geriatric Assessment into Clinical Trials and Practice
There are great differences between elderly individuals. 34 . In this study, elderly patients (aged >70 years) with unresectable stage III NSCLCs were selected on the basis of the inclusion and exclusion criteria. In addition, patients must be certified fit by CGA. The authors concluded that CGA may help to select fit elderly patients eligible for standard chemoradiotherapy with a satisfactory risk-to-benefit ratio. The NVALT25-ELDAPT trial is ongoing to develop a reliable and clinically applicable screening tool to distinguish medically fit individuals from frail patients 35 . From the results of this study, treatment selection can be optimized and the best possible outcomes for each individual older patients with stage III NSCLC can be achieved.
Future Prospects
In the subject of oncology regarding older and vulnerable patients, it is important to avoid over treatment and under treatment. A recommended approach is patient selection using tools such as CGA. If we can divide elderly patients into subgroups by using geriatric assessment, elderly patients can be given appropriate treatments according to their conditions. Randomized controlled trials usually have stringent inclusion and exclusion criteria, and only highly selected elderly patients can enroll in these clinical trials. However, many elderly people with cancer are unable to participate because of comorbidities, organ dysfunction, their general conditions, and so on. To investigate a wide range of older and less fit adults with cancer, pragmatic clinical trials that enable broad eligibility; treatment modification based on clinical necessity; and representation of more meaningful clinical endpoints, rather than hard endpoints, are required 36, 37 . Therefore, pragmatic clinical trials with realworld effectiveness that is relevant to the general older population with cancer should be established.
